International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Abstract

Scientific advances over the 35 years since AIDS was first recognized as a new disease, have put us on a clear path towards ending the HIV/AIDS pandemic. Scaling-up access to antiretroviral therapy (ART) and HIV prevention strategies, such as pre-exposure prophylaxis, could dramatically decrease HIV-related deaths and the rate of new HIV infections. Current and future scientific advances, notably in HIV vaccine and cure research, will accelerate this process. Two major directions in HIV vaccine development will be discussed: building on the results from RV 144, the clinical trial in Thailand that resulted in the first modest signal of efficacy for a HIV vaccine; and structure-based immunogen design to elicit broadly neutralizing antibodies. Cure research has accelerated greatly over the past few years in two areas. The first is the prospect of eradicating the HIV reservoir altogether (i.e. a classic cure), which might involve novel latency-reversing and immunotoxic regimens and gene editing techniques to create a host cellular environment that does not allow HIV replication. The second approach involves controlling viral rebound following discontinuation of ART to achieve sustained virological remission employing strategies, such as passive transfer of broadly neutralizing antibodies and therapeutic vaccination. In 2016, the arsenal of scientifically proven interventions available, as well as the hope of others to come, offer unprecedented opportunities to make major gains in the fight against HIV/AIDS. With a major global commitment to implement these scientific advances, the end of the HIV/AIDS pandemic is now achievable.

Social Media Interventions to Promote HIV Testing, Linkage, Adherence, and Retention: Systematic Review and Meta-Analysis

“…Of the 981 articles and abstracts, 26 studies met our inclusion criteria [ 26 - 51 ] ( Figure 1 ). Of the 26 studies, eight were RCTs [ 28 , 33 , 41 , 42 , 46 , 47 , 49 , 50 ] and 18 were observational studies [ 26 , 27 , 29 - 32 , 34 - 40 , 43 - 45 , 48 , 51 ] ( Table 1 ). These studies were implemented in 10 countries from 2007-2015 and published from 2011-2016.…”

“…These studies were implemented in 10 countries from 2007-2015 and published from 2011-2016. In total, 18 studies were from four high-income countries as defined by the World Bank [ 28 , 29 , 31 - 38 , 40 , 42 - 45 , 47 , 48 , 50 ], 10 studies were from the United States [ 28 , 33 - 35 , 38 , 42 , 43 , 45 , 47 , 50 ], five from the United Kingdom [ 29 , 31 , 32 , 36 , 48 ], two each from Australia [ 40 , 44 ], China [ 46 , 51 ], and Thailand [ 26 , 27 ], and one each from Taiwan [ 37 ], India [ 41 ], Peru [ 49 ], Mexico [ 30 ], and Guatemala [ 39 ]. The reach of social media interventions varied from 55 to over 17,000 individuals.…”

“…MSM were the primary population included in the reviewed social media interventions. All of the included studies contained MSM populations, and five also covered transgender individuals [ 26 , 27 , 35 , 42 , 46 ]. In three studies, MSM with the following specific characteristics were included: young MSM [ 28 ], young black MSM [ 47 ], and MSM living with HIV [ 33 ].…”

Cost-effectiveness of screening for HIV in primary care: a health economics modelling analysis

“… 29 , 30 , 31 PrEP cost-effectiveness estimates have ranged from cost-saving (Canada 30 ) to US$160 000 per QALY gained (USA 29 ). Preliminary cost-effectiveness results of MSM PrEP in the UK have also varied, from £26 300 32 to cost-saving per QALY gained 33 in base case scenarios. The latter ICER used an 80 year time horizon, 33 whereas we report cost-effectiveness at 40 years after the start of the intervention.…”

“…Preliminary cost-effectiveness results of MSM PrEP in the UK have also varied, from £26 300 32 to cost-saving per QALY gained 33 in base case scenarios. The latter ICER used an 80 year time horizon, 33 whereas we report cost-effectiveness at 40 years after the start of the intervention. Cost-effectiveness of these HIV prevention interventions increase with time and so RHIVA2 is of comparable cost-effectiveness.…”